Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Hart

Sports Medicine Cedar Rapids, IA Medical Doctor

NPI 1497169007 CMS profile 434286

202 10Th St Se, Cedar Rapids, IA 52403

Open in the dashboard

General payments

$37,233

184 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Hart of Cedar Rapids, IA is reported in the CMS Open Payments database as having received $37,233 across 184 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $941 15
2024 General $1,980 20
2023 General $2,242 37
2022 General $5,580 50
2021 General $2,367 33
2020 General $3,904 26
2019 General $20,219 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Hart
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to John Hart were reported at $941. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year John Hart Sports Medicine median Middle half National median
2019 $20,219 $1,176 $199–$4,249 $163
2020 $3,904 $708 $96–$2,890 $114
2021 $2,367 $1,213 $152–$3,994 $132
2022 $5,580 $1,230 $159–$3,998 $149
2023 $2,242 $584 $146–$2,836 $160
2024 $1,980 $628 $163–$3,168 $164
2025 $941 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $22,404 21 payments
  2. Stryker Corporation $11,237 139 payments
  3. Gemini Mountain Medical, LLC $1,560 1 payment
  4. Wardlow Enterprises $1,026 4 payments
  5. Zimmer Biomet Holdings, Inc. $802 13 payments
  6. Encore Medical, LP $90 1 payment
  7. DePuy Synthes Sales Inc. $74 2 payments
  8. Vertex Pharmaceuticals Incorporated $28 2 payments
  9. Smith+Nephew, Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $20,000 1 payment
  2. Food and Beverage $9,429 158 payments
  3. Travel and Lodging $4,386 22 payments
  4. Education $3,418 3 payments
Products named General payments · program years 2019–2025
  1. BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION $1,643 30 payments
  2. MAKO Knees, Hips $1,185 10 payments
  3. VARIAX $1,069 14 payments
  4. PRO $1,005 2 payments
  5. AEQUALIS PERFORM $682 10 payments
  6. MAKO Knees, Hips $612 9 payments
  7. INSPACE $581 12 payments
  8. SALVATION $521 3 payments
  9. GAMMA $515 8 payments
  10. SIMPLICITI $447 4 payments
  11. Other $4,235 59 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

611

Median for Orthopedic Surgery: 203

Drug cost

$1,959

Median for Orthopedic Surgery: $1,433

Branded share of claims

11.1%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 150 $895
Ondansetron Odt Ondansetron Brand 54 $319
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 14 $143
Amoxicillin Generic 161 $140
Meloxicam Generic 78 $117
Tramadol Hcl Generic 37 $88
Ondansetron Hcl Generic 30 $63
Naproxen Generic 24 $59
Tranexamic Acid Generic 11 $37
Cephalexin Generic 26 $36

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$181,659

Of which drugs: $14,325

Medicare patients

441

Average age 74

Services billed

5,589

269 women, 172 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Depression 30%
Diabetes 27%
Ischemic heart disease 27%
Chronic kidney disease 24%
Heart failure 18%
Osteoporosis 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 27 1,872 $13,150
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 182 1,592 $1,127

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

184 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record